Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Provided herein are modified amino acids comprising an azido group, polypeptides, antibodies and conjugates comprising the modified amino acids, and methods of producing the polypeptides, antibodies and conjugates comprising the modified amino acids. The polypeptides, antibodies and conjugates are useful in methods of treatment and prevention, methods of detection and methods of diagnosis.
Core Innovation
The disclosure concerns azide-containing modified amino acid residues, including residues of formula IIc, and polypeptides containing such residues linked directly or through linking moieties to payloads. The incorporated azide supports selective azide-alkyne cycloaddition to attach payloads such as labels, water-soluble polymeric materials, or cytotoxic compounds. Reported examples describe reaction of analogs with DBCO and site-specific incorporation of compound (30) into GFP, GM-CSF, and full-length IgG.
Described antibody formats include immunoglobulin polypeptides and antibody fragments, with payload examples encompassing maytansinoids and DM-1. The approach addresses heterogeneous conventional conjugation through site-specific incorporation and selective payload attachment via specified linking moieties to improve conjugate uniformity, yield, and retained activity. The disclosure further describes therapeutic, diagnostic, and detection uses, as well as polymers for altering properties such as serum half-life.
Claims Coverage
The claims identify three independent claims covering three inventive features directed to polypeptide-linked-to-a-payload compositions.
Polypeptide linked to a payload with a formula IIc amino acid residue
Claim 1 covers a polypeptide polymer of amino acid residues containing one or more residues according to formula IIc, or a salt thereof, with W4 defined as C1–C10 alkylene, linked to a payload comprising a label, a polymeric material, a cytotoxic compound, or a combination thereof.
Polypeptide linked to a payload through a specified linking moiety
Claim 11 covers a polypeptide containing one or more amino acid residues of the stated formula, or a salt thereof, with W4 defined as alkylene, connected through a linking moiety comprising one or more listed alkylene, heteroalkylene, arylene, or heteroarylene groups to a payload comprising a polymeric material, a label, a cytotoxic compound, or a combination thereof.
Payload-linked immunoglobulin polypeptide
Claim 20 covers a polypeptide selected from listed immunoglobulin polypeptides and antibody fragments containing one or more amino acid residues of the stated formula, or a salt thereof, with W4 defined as C1–C10 alkylene, connected through a linking moiety comprising listed alkylene, heteroalkylene, arylene, or heteroarylene groups to a payload comprising a label, a cytotoxic compound, or both.
The independent claims cover formula-defined amino acid residues in payload-linked polypeptides with specified linking moieties and payload classes, with claim 20 specifically directed to immunoglobulin and antibody-fragment formats.
Stated Advantages
The approach aims to improve conjugate uniformity, yield, and retained activity relative to heterogeneous conventional conjugation.
Compounds (30) and (40) react with DBCO faster than the reference compound p-azidophenylalanine.
Compounds (1) and (30) achieve near-quantitative reaction with DBCO-NH₂.
Water-soluble polymers, including polyethylene glycol, are described for altering properties such as serum half-life.
Documented Applications
Site-specific incorporation of azido-bearing modified amino acids, including compound (30), into GFP, GM-CSF, and full-length IgG or antibodies, followed by payload attachment.
Therapeutic, diagnostic, and detection uses, as well as pharmaceutical formulations for polypeptide-payload conjugates.
Interested in licensing this patent?